Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses the pooled analysis of three trials which all analyzed the outcome of mantle cell lymphoma (MCL) patients treated with ibrutinib (NCT01236391, NCT01599949 and NCT01646021). Overall, there were 370 patients with a complete remission (CR) of 20% and an overall response rate (ORR) of 66%. In patients who achieved CR, over 90% were still alive after 2 years. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up